Truvada

Selected form

Treatment option: Infection, Pre-Exposure Prophylaxis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Truvada

Understanding Truvada

Truvada is a prescription medication used in the management and prevention of human immunodeficiency virus type 1 (HIV-1). It is a fixed-dose combination product containing two active pharmaceutical ingredients: emtricitabine and tenofovir disoproxil fumarate.

Therapeutic Class and Composition

Both components of Truvada belong to a class of medications known as nucleoside reverse transcriptase inhibitors (NRTIs). These substances are designed to interfere with the replication process of the virus. By combining two different NRTIs into a single tablet, the medication targets the viral life cycle at multiple points.

Primary Uses

Truvada is utilized in two distinct clinical contexts:

HIV-1 Treatment: When used for treatment, Truvada is administered in combination with other antiretroviral agents. It is not a cure for HIV-1 or AIDS, but it helps decrease the amount of virus in the body.
Pre-Exposure Prophylaxis (PrEP): In this context, the medication is taken by individuals who do not have HIV-1 but are at an increased risk of acquiring the virus through sexual activity. When used as PrEP, it is intended to reduce the risk of new HIV-1 infection.

Mechanism of Action

The medication works by inhibiting an enzyme called reverse transcriptase. HIV-1 requires this enzyme to copy its genetic material and spread throughout the body. Emtricitabine and tenofovir disoproxil fumarate act as decoys that integrate into the viral DNA chain, effectively terminating the chain's growth and preventing the virus from multiplying.

Regulatory References

EMA Truvada EPAR

What side effects are possible with Truvada?

Possible Side Effects and Safety Information

The official safety profile for Truvada (Emtricitabine/Tenofovir disoproxil fumarate) is characterized by common, expected adverse reactions and specific serious warnings related to the drug's components, as documented by government regulatory agencies.

Adverse Reaction Scope

Classification Tier	Examples of Documented Effects	System-Organ Class Focus
Very Common (ge 10%)	Headache, Diarrhoea, Nausea, Hypophosphataemia	Gastrointestinal, Nervous System, Metabolic
Common (ge 1% to < 10%)	Dizziness, Vomiting, Fatigue, Rash, Abdominal pain	General Disorders, Skin, Nervous System

Serious Adverse Reactions

Regulatory documents highlight the risk of serious, although rare, adverse reactions, including: Lactic Acidosis and Severe Hepatomegaly with Steatosis (a class-wide warning for nucleoside analogs), and New Onset or Worsening Renal Impairment, which can manifest as Acute Renal Failure or Fanconi Syndrome. Renal and urinary disorders, along with musculoskeletal effects like decreased Bone Mineral Density (BMD), are key areas of safety focus for the Tenofovir component, particularly with long-term exposure.

Population-Specific Safety Constraints

A critical safety consideration applies to individuals co-infected with Hepatitis B Virus (HBV). Discontinuation of this medicine in these patients can result in Severe Acute Exacerbations of Hepatitis B, necessitating close monitoring as stated in the label. The medicine is also not recommended for use in individuals with severe renal impairment (creatinine clearance less than 30 mL/min).

Connection to the Overall Safety Profile

The official safety information structures the risk profile by classifying the high-frequency events separately from the rare, clinically significant adverse reactions, particularly those affecting the liver and kidneys. The explicit warnings regarding Hepatitis B exacerbation and the need for renal function monitoring underscore the primary non-infectious safety considerations dictated by regulatory authorities.

Overdose and Emergency Response

Suspected overdose with Truvada (emtricitabine and tenofovir disoproxil fumarate) requires immediate medical attention, as stated in regulatory guidelines. The official overdose profile is defined by the potential exacerbation of severe toxicities associated with nucleoside analogues, which include potentially life-threatening outcomes.

Documented Manifestations and Severe Risks

An overdose may exacerbate the risk of Lactic Acidosis and Severe Hepatomegaly with Steatosis (enlargement of the liver with fat accumulation), which are formally recognized as potentially fatal complications. Symptoms to monitor may include unusual muscle pain, unexpected weakness, shortness of breath, or abdominal pain suggesting Lactic Acidosis. Signs of Hepatotoxicity, such as jaundice (yellowing of the skin or eyes), also mandate urgent follow-up. Acute overdose can increase the risk of severe renal toxicity, including Acute Renal Failure, particularly in individuals with pre-existing kidney impairment.

Required Emergency Actions

The official instruction for a suspected overdose is to contact a poison control center or emergency room at once. There is no specific antidote known for Truvada. Management is entirely supportive and symptomatic, focusing on the patient's clinical status. Regulatory documentation notes that the active ingredients are partially removable from the bloodstream via hemodialysis. Close clinical and laboratory follow-up is required in all overdose scenarios.

Therapeutic Uses of Truvada

Primary Uses and Therapeutic Benefits of Truvada

The medication is commonly used across two core therapeutic domains related to Human Immunodeficiency Virus Type 1 (HIV-1) infection. Truvada may be part of symptomatic management within combination therapy for treating established HIV-1 infection.

Treatment and Prevention Overview

Truvada is applied in two main contexts: for the treatment of established HIV-1 infection and for Pre-exposure Prophylaxis (PrEP) in HIV-negative individuals at high risk. For those managing the chronic condition, this medicine is generally used for helping to suppress the viral load and supports immune function and the management of cell counts. This assists with maintaining functional stability and contributes to easing the overall symptom load.

For prevention, the medicine is relevant for scenarios involving serodiscordant couples and other high-risk situations, providing supportive relief that helps patients cope more steadily with the concern of viral acquisition.

“The approach is relevant for supporting immune function and helping to address symptomatic concerns related to chronic viral presence.”

Quick Fact: Symptom Management
Main Benefit	Contributes to easing the overall symptom load by helping to suppress viral activity.
Use Context	Applied in clinical settings that involve chronic or high-risk infection patterns.

Regulatory References

European Medicines Agency (EMA) overview

Eligibility and Restrictions for Use

The eligibility profile for Truvada, as documented by regulatory authorities, defines specific population groups who can and cannot use the medication.

Eligibility Domain	Official Status and Restriction
Absolute Contraindications	Use for Pre-exposure Prophylaxis (PrEP) is formally contraindicated if the individual's HIV-1 status is unknown or confirmed positive. The fixed-dose combination tablet is also not recommended for HIV-infected adults with severe renal impairment (Creatinine Clearance, CrCl, <30 mL/min) or those requiring hemodialysis.
Renal Function Thresholds	For HIV-uninfected individuals using Truvada for PrEP, use is not recommended if the estimated CrCl is below 60 mL/min. Use for HIV treatment in moderate renal impairment (CrCl 30–49 mL/min) is similarly not recommended, as the fixed-dose formulation prevents the necessary adjustment of individual components.
Age and Weight	Pediatric eligibility is strictly determined by weight: patients must weigh at least 17 kg for HIV treatment. Adolescents must weigh at least 35 kg to be eligible for PrEP. Use in children below these specific weight thresholds is not established.
Comorbidities and Restrictions	Individuals must undergo testing for chronic Hepatitis B virus (HBV) infection prior to initiation. Furthermore, the medicine must not be co-administered with any other products containing emtricitabine, tenofovir disoproxil fumarate, or lamivudine.

The regulatory documents confirm that PrEP use is considered an acceptable option for continuation throughout both pregnancy and breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation defines specific interactions for Truvada (Emtricitabine and Tenofovir disoproxil fumarate), primarily concerning pharmacokinetic and pharmacodynamic relationships with co-administered substances.

Prohibited Combinations and Restrictions

Co-administration is contraindicated with any medicinal products containing Lamivudine, Adefovir dipivoxil, Emtricitabine, or any form of Tenofovir. This restriction prevents redundancy and the potential for increased exposure to active drug components. Furthermore, official labeling requires the avoidance of concurrent or recent use with nephrotoxic drugs, such as certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), due to competition for active renal tubular secretion and the risk of additive renal toxicity.

Documented Exposure-Altering Effects

Co-administration with several ritonavir-boosted protease inhibitors (e.g., Lopinavir/ritonavir, Darunavir/ritonavir) formally increases tenofovir concentrations in the blood. Conversely, the tenofovir component is documented to increase the plasma concentration of Didanosine. To mitigate one of these effects, Atazanavir must be co-administered with Ritonavir when combined with Truvada. Exposure to both components increases in individuals with pre-existing or worsening renal impairment.

Other Interactions

The absorption of the tenofovir component is optimized when the tablet is taken with food. Separately, the substance Orlistat may inhibit the absorption of Truvada's components.

Mechanism of Action

Truvada's mechanism of action is defined by a complementary dual inhibition strategy, primarily targeting the viral Reverse Transcriptase (RT) enzyme. The two components, Emtricitabine and Tenofovir disoproxil fumarate, are prodrugs that undergo intracellular phosphorylation into their active metabolites (triphosphate/diphosphate forms). These active metabolites function as competitive inhibitors by structurally mimicking the natural genetic building blocks required for viral replication. Once incorporated into the nascent proviral DNA chain, these faulty analogs prevent the formation of the next phosphodiester bond. This specific molecular event triggers DNA chain termination, which results in the suppression of proviral DNA synthesis. This dual action is crucial, creating a barrier against the mutational evasion of the Reverse Transcriptase. The mechanism is highly selective, acting only against the active enzyme during the replication cycle, and has no inhibitory effect on the viral genetic material already integrated into the host cell's provirus.

Dosage and Administration Information

How to Use Truvada

Truvada is administered via the oral route as a fixed-dose combination film-coated tablet containing 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate for most adults. The standard dosing regimen for both the treatment of HIV-1 and Pre-exposure Prophylaxis (PrEP) is one tablet once daily. This frequency pattern requires strict adherence for both long-term applications.

Administration Conditions and Dosing Adjustments

Category	Official Instruction
Timing in relation to meals	Can be taken with or without food; taking it with food is preferable.
Tablet Preparation	The tablet may be swallowed whole, or it can be disintegrated in approximately 100 mL of water, orange juice, or grape juice and taken immediately.
Missed Dose Handling	If missed by less than 12 hours, take immediately; if missed by more than 12 hours, skip the dose and resume the normal daily schedule.
Renal Impairment	For HIV-1 treatment, the dosing interval is adjusted to every 48 hours for patients with moderate renal impairment (CrCl 30–49 mL/min). Truvada is not recommended for PrEP if CrCl < 60 mL/min.

Pediatric and Procedural Use

Administration for pediatric patients is weight-based, utilizing lower-strength FDC tablets for children weighing ge 17 kg who are using it for treatment. The overall protocol mandates routine renal function monitoring prior to and during use, including the assessment of Creatinine Clearance (CrCl), as this laboratory value dictates the appropriate dosing frequency and PrEP eligibility. The instructions thus structure a precise, individualized pattern for long-term use, governed by patient weight and kidney function thresholds.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Truvada

Research Evidence for Truvada in HIV-1 Treatment

The research base for this combination includes Randomized Controlled Trials (RCTs) that examined the active components when used as part of combination antiretroviral regimens for managing established HIV-1 infection. These trials primarily measured two key outcomes: virologic suppression and immunologic restoration. Virologic suppression refers to reducing the amount of HIV-1 in the blood (known as the viral load) below a detectable level. Immunologic restoration involves monitoring changes in CD4+ T-cell counts, which are a key measure used in HIV research.

Studies monitored how many participants receiving the combination regimen were observed to have a viral load below detectable limits at specific intermediate time points, such as 48 weeks. Findings from the trials monitored patterns showing that many participants had higher CD4+ T-cell counts at the end of the observation period than at the start. The largest body of evidence describing these patterns involves treatment-naïve adults—individuals who had not received prior HIV treatment.

Research Evidence for Truvada in Pre-Exposure Prophylaxis (PrEP)

The evidence for Pre-Exposure Prophylaxis (PrEP) includes several large, multinational Randomized, Placebo-Controlled Trials. Researchers closely monitored the incidence of new HIV-1 infections (seroconversion). Studies examined the difference in the rate of new HIV infection observed between the active medicine group and the placebo group.

The research examined patterns showing that drug adherence was associated with the observed outcomes. Findings were mixed across different study populations. Researchers noted an association between low levels of drug detection and the outcomes observed in those participants. Subsequent studies monitored patterns showing that detectable drug levels were associated with a lower rate of new HIV infections in the observed populations.

What the Research Shows Is Still Uncertain

Data for certain groups remain insufficient. For instance, there is limited information for long-term outcomes related to drug-drug interactions, particularly in transgender women using hormone therapy. This illustrates a current research gap where more data may be needed. Furthermore, the persistence of study findings over many years is primarily explored through extended observational cohorts.

Key Studies & References Efficacy Trial Results - PrEPWatch (Document referencing FEM-PrEP and adherence outcomes)

How should Truvada be stored and disposed of?

Storage and Disposal of Truvada

Truvada (Emtricitabine/Tenofovir Disoproxil Fumarate) must be stored strictly according to regulatory labeling to maintain its stability.

Official Storage Conditions

Requirement	Details
Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection	Keep the medicine in its original container, tightly closed, and protect from excessive heat and moisture (do not store in a bathroom).
Child Safety	Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired medication must be safely discarded. Patients should consult a pharmacist about local drug take-back programs. If a program is unavailable, tablets can be mixed with an undesirable substance (like coffee grounds), sealed in a container, and discarded in the household trash. Truvada should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.